QuickView for Thy-1;jsessionid=011CF923678866240A0AFA39DB3FF7BC;jsessionid=469EB5DB5BA323E16AE04AF9D11394C5;jsessionid=8E43C2EF0A07BE06C199C1A34AF33D77;jsessionid=2900716895C7B22D189A0773046E2D52;jsessionid=CA952A44FE01AE77031BFB7DBD162FCB;jsessionid=B054213316647F33E3F328867B443D82;jsessionid=92F91E820C07525D2105E42DD3E9FD9C;jsessionid=D5BEEE6D7352FA5B6E1592E27A58620D (gene)

1. Long-term follow-up of donor-derived CD7 CAR T-cell therapy in patients with T-cell acute lymphoblas…
2. Donor CD7 Chimeric Antigen Receptor T Cell Bridging to Allogeneic Hematopoietic Stem Cell Transplant…
3. Expression of CD7 and its correlation with prognosis in patients with NK/T-cell lymphoma].
4. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed a…
5. An antibody-drug conjugate with intracellular drug release properties showing specific cytotoxicity …

There were no clinical trials for Thy-1;jsessionid=011CF923678866240A0AFA39DB3FF7BC;jsessionid=469EB5DB5BA323E16AE04AF9D11394C5;jsessionid=8E43C2EF0A07BE06C199C1A34AF33D77;jsessionid=2900716895C7B22D189A0773046E2D52;jsessionid=CA952A44FE01AE77031BFB7DBD162FCB;jsessionid=B054213316647F33E3F328867B443D82;jsessionid=92F91E820C07525D2105E42DD3E9FD9C;jsessionid=D5BEEE6D7352FA5B6E1592E27A58620D